
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
DMRT1 CRISPR Activation Plasmid (h) | sc-402856-ACT | 20 µg | $397.00 | |||
DMRT1 CRISPR Activation Plasmid (h2) | sc-402856-ACT-2 | 20 µg | $397.00 |
DMRT1 (doublesex and mab-3 related transcription factor 1) encodes a zinc-finger DNA-binding transcription factor that plays a central role in human gonadal development and maintenance of male germ cell fate. DMRT1 regulates transcriptional programs controlling sex determination, Sertoli cell differentiation, and spermatogonial proliferation and differentiation, integrating with broader networks that include SOX9- and retinoic acid–responsive pathways. Altered DMRT1 dosage or regulation has been associated with disorders of sex development, impaired spermatogenesis, and gonadal dysgenesis, making it a valuable target for mechanistic studies of reproductive biology. In addition, dysregulated DMRT1 activity has been reported in select tumor contexts, supporting its use in investigating lineage specification and transcriptional control in disease-relevant models.
DMRT1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous DMRT1 expression without altering the underlying DNA sequence.
DMRT1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the DMRT1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the DMRT1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous DMRT1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native DMRT1 locus and enabling the study of DMRT1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of DMRT1 pathway restoration in tumor cells with silenced or reduced DMRT1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.